financetom
Business
financetom
/
Business
/
Parliamentary Budget Watchdog Sees Canada's Federal Capital Spending on Cash Basis for Next Five Years Mostly in Defense
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Parliamentary Budget Watchdog Sees Canada's Federal Capital Spending on Cash Basis for Next Five Years Mostly in Defense
Aug 14, 2025 8:18 AM

10:51 AM EDT, 08/14/2025 (MT Newswires) -- Canada's government in the spring announced a shift in its fiscal policy to increase the rate of capital investment and place greater emphasis on the acquisition of defense-related assets, noted the Parliamentary Budget Officer (PBO).

The PBO on Thursday said it expanded the capital budget module in its fiscal model. Specifically, the model will now allow it to provide parliamentarians with a five-year projection of federal capital spending, amortization, and the accumulation of assets.

Overall, PBO's new capital budgeting approach better reflects the anticipated increase in federal capital investments. Federal capital amortization expenses are $7.1 billion higher over the next five years compared with PBO's March 2025 Economic and Fiscal Outlook. This mostly reflects better data shared by National Defence.

For the first time, the PBO is now able to project federal capital spending, on a cash basis, of $128 billion for the next five years. Almost two-thirds, or $83 billion, relates to National Defence, it added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US sanctions hit Serbia's Russian-owned oil firm NIS
US sanctions hit Serbia's Russian-owned oil firm NIS
Oct 9, 2025
BELGRADE (Reuters) -The United States imposed sanctions on Serbia's Russian-owned oil company NIS on Thursday, prompting neighbouring Croatia to cut crude supplies and raising concerns that the country's sole refinery may halt operations within weeks.  Without deliveries, the NIS refinery, which supplies most of Serbia's oil products, including gasoline and jet fuel, will struggle to operate beyond November 1, Serbia's...
Resource Innovations Acquires Shifted Energy, Creating the Industry's First Integrated Turnkey Utility DSM and Edge DERMS Platform
Resource Innovations Acquires Shifted Energy, Creating the Industry's First Integrated Turnkey Utility DSM and Edge DERMS Platform
Oct 9, 2025
SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- Resource Innovations (RI), a leading utility software and consulting platform, today announced the acquisition of Shifted Energy, a Honolulu-based company recognized for its pioneering distributed-energy resource management system (DERMS) technology and commitment to energy equity. With U.S. electricity demand projected to outpace capacity by nearly 200 gigawatts in the coming years, utilities face...
Share One and VisiFI Join Forces Under a New Brand: Deda Sphere Inc.
Share One and VisiFI Join Forces Under a New Brand: Deda Sphere Inc.
Oct 9, 2025
Merger Creates a Stronger, More Connected Partner Driving Innovation for Credit Unions. MEMPHIS, Tenn.--(BUSINESS WIRE)-- Share One and VisiFI, both providers of core and digital banking solutions under Dedagroup North America, today announced they will unite under a single new brand: Deda Sphere. The merger, unanimously approved by both companies’ boards, took effect October 1, 2025. This press release features...
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says
Oct 9, 2025
10:59 AM EDT, 10/09/2025 (MT Newswires) -- Ovid Therapeutics ( OVID ) is advancing its epilepsy drug candidate OV329 following encouraging early-stage clinical data that suggest best-in-class potential, Oppenheimer said in a note Wednesday. Phase 1 data showed OV329, a GABA-aminotransferase inhibitor, demonstrated a favorable safety and tolerability profile, including no ocular findings at doses up to 5 milligrams, while...
Copyright 2023-2026 - www.financetom.com All Rights Reserved